All posts by student

Home | Neurosciences PhD Program | Stanford Medicine

The Stanford Neurosciences Interdepartmental Program (IDP) offers interdisciplinary training leading to a Ph.D. in Neuroscience. The primary goal of the program is to train students to become leaders in neuroscience research, education and outreach. Graduates of the program will be innovators, investigators, and teachers whose programs and pursuits are founded on research. The signature feature of the Stanford Neurosciences IDP is the combination of outstanding faculty researchers and exceedingly bright, energetic students in a community that shares a firm and longstanding commitment to understanding the nervous system at all its levels of function.

See the original post:
Home | Neurosciences PhD Program | Stanford Medicine

From fantasy to possibility – The Statesman

A landmark study suggests that scientists could soon edit out genetic mutations to prevent babies being born with diseases.

The technique could eventually let doctors remove inherited conditions from embryos before they go on to become a child. That, in turn, opens the possibility for inherited diseases to be wiped out entirely, according to doctors. But experts have warned that urgent work is needed to answer the ethical and legal questions surrounding the work.

Though the scientists only edited out mutations that could cause diseases, it modified the nuclear DNA that sits right at the heart of the cell, which also influences personal characteristics such as intelligence, height, facial appearance and eye colour.

The breakthrough means that the possibility of germline genome editing has moved from future fantasy to the world of possibility, and the debate about its use, outside of fears about the safety of the technology, needs to run to catch up, said Professor Peter Braude from Kings College London.

Scientists warned that soon the public could demand such treatment and that the world might not be ready. Families with genetic diseases have a strong drive to find cures, said Yalda Jamshidi, reader in genomic medicine at St Georges, University of London.

Whilst we are just beginning to understand the complexity of genetic disease, gene-editing will likely become acceptable when its potential benefits, both to individuals and to the broader society, exceeds its risks. The new research, published in Nature, marks the first time the powerful Crispr-Cas9 tool has been used to fix mutations. The US study destroyed the embryos after just a few days and the work remains at an experimental stage. In the study, scientists fertilised donor eggs with sperm that included a gene that causes a type of heart failure.

As the eggs were fertilised, they also applied the gene-editing tool, which works like a pair of specific scissors and cuts away the defective parts of the gene. When those problematic parts are cut away, the cells can repair themselves with the healthy versions and so get rid of the mutation that causes the disease. Some 42 out of 58 embryos were fixed so that they didnt carry the mutation stopping a disease that usually has a 50 per cent chance of being passed on.

If those embryos had been allowed to develop into children, then they would no longer have carried the disease. That would stop them from being vulnerable to hypertrophic cardiomyopathy and would save their children, too. Every generation on would carry this repair because weve removed the disease-causing gene variant from that familys lineage, said Dr Shoukhrat Mitalipov, from Oregon Health and Science University, who led the study. By using this technique, its possible to reduce the burden of this inheritable disease on the family and eventually the human population.

The heart problem is just one of more than 10,000 conditions that are caused by an error in the gene. The same tool could be used to cut out faults for all of those, and eventually be used to target cancer mutations. The work could lead to treatments that would be given to patients, once it becomes more efficient and safe. Using such a treatment on humans is illegal in both the US and the UK but some experts expect that law will soon be changed, and that the legal and ethical frameworks need to catch up with the technology. There is some suggestion that the editing work could take place in the UK.

Though using the research as treatment is illegal there as well as the US, the regulatory barriers are much higher in America and look unlikely to be changed. In the US, there are various regulations and restrictions on how embryos can be edited, including stipulations that such work cant be carried out with taxpayers money. UK regulators are more relaxed and liberal about those restrictions, leading to suggestions that it could eventually become the home of such work in the West.

The UK has become the first country that allows mitochondrial replacement therapy, another treatment that opponents warn could allow for the creation of designer babies. UK researchers can apply for a licence to edit human embryos in research, but offering it as a treatment is currently illegal, said a spokesperson for the Human Fertilisation and Embryology Authority, which would regulate any such experiments.

Introducing new, controversial techniques is not just about developing the science gene editing would need to offer new options to couples at risk of having a child with a genetic disease, beyond current treatments like embryo testing. Our experience of introducing mitochondrial donation in the UK shows that high-quality public discussion about the ethics of new treatments, expert scientific advice and a robust regulatory system are crucial when considering new treatments of this kind.

Doctors said that any change in the law would have to strictly keep such treatment to being used for medical reasons, and not for designer babies that have other characteristics edited out. It may be that some countries never permit germline genome editing because of moral and ethical concerns, said Professor Joyce Harper from University College London. If the law in the UK was changed to allow genome editing, it would be highly regulated by the Human Fertilisation and Embryology Authority, as is PGD, to ensure it is only used for medical reasons.

But that work has already received significant opposition. Dr David King, director of the Human Genetics Alert, which opposes all tampering with the human genome, said, If irresponsible scientists are not stopped, the world may soon be presented with a fait accompli of the first genetically-modified baby.

We call on governments and international organisations to wake up and pass an immediate global ban on creating cloned or GM babies, before it is too late. Professor Robin Lovell-Badge from the Francis Crick Institute said the research only appears to work when the father is carrying the defective gene, and that it would not work for more sophisticated alterations.

The possibility of producing designer babies, which is unjustified in any case, is now even further away, he said.

(The independent)

Read more:
From fantasy to possibility - The Statesman

Global Immunology Drugs Market to 2022; New Report Launched – Digital Journal

DrugPipeline.net has announced the addition of Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth research report to their website http://www.DrugPipeline.net

This press release was orginally distributed by SBWire

Bangalore, India -- (SBWIRE) -- 08/07/2017 -- Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

Summary

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.

A number of therapies have been approved for immunological disorders, including the largely genericized disease-modifying anti-rheumatic drug (DMARD) class of small molecule drugs. However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. There is currently no cure for immunological disorders due to the highly complex nature of the immune system and the fact that many components of the pathophysiological states of these diseases have roles in the healthy immune system.

Autoimmune disorders are currently incurable, and treatment is aimed at managing the disease, in order to reduce the severity of its symptoms and lower the risk of associated co-morbidities. Cytokines and their receptors, such as Tumor Necrosis Factor-? and Interleukin-6 are the most effective and most common therapies used in immunology. This class of compounds has been the most commercially successful in the past decade, particularly in the RA market, with many clinical trials underway across various immunological indications. The market for immunological disorders is largely accounted for by premium products, with only a relatively small revenue share accounted for by generics and biosimilars.

Inflectra, a biosimilar of Remicade was recently approved by the FDA in 2016. However, the gradual uptake of biosimilars such as Inflectra is not expected to act as a strong growth driver for the biosimilar segment within the forecast period. This therefore means existing products such as Remicade are expected to maintain high revenues during the forecast period

Although there is a high degree of failure and uncertainty in R&D of immunological drugs, there are 2,054 drugs in active development in the immunology pipeline. In the long-term, this is expected to drive growth in this market in spite of the anticipated approval of biosimilars for key blockbuster drugs and resultant erosion of revenues. Cytokines and their receptors account for the largest single segment of each of the pipelines which make up the largest individual class.

The report focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease (The two major types of Inflammatory bowel disease covered in this report are Ulcerative colitis and Crohn's disease). With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in SLE, increasing the need for extensive R&D within this area.

Scope

- Global revenues for the immunology market are forecast to grow at a compound annual growth rate of 3.63%, from $57.7 billion in 2015 to $74.1 billion in 2022.

- Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

- The immunological disorders pipeline is large and diverse, and contains 2,054 products. How does the composition of the pipeline compare with that of the existing market?

- What molecular targets and molecule types are most commonly being trialed in pipeline products in the key indications?

- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?

- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the immunology market set to change?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis

- Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players

- Analyze the immunological disorders pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications

- Understand the growth in patient epidemiology and market revenues for the immunology market, globally and across the key players and product types

- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various immunological disorders.

- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

Spanning over 140 pages "Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth" report covers Introduction, Key Marketed Products, Pipeline Landscape Assessment, Multi-scenario Market Forecast to 2022, Company Analysis and Positioning, Strategic Consolidations, Appendix.

For more information Visit at: http://www.drugpipeline.net/gbi-research/global-immunology-drugs-market-2022-increasing-prevalence-repositioning-opportunities

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Pain Drug Development Pipeline Review, 2017 - Visit at - http://www.drugpipeline.net/gbi-research/pain-drug-development-pipeline-review-2017

Skeletal Disease Drug Development Pipeline Review, 2017 - Visit at - http://www.drugpipeline.net/gbi-research/skeletal-disease-drug-development-pipeline-review-2017

About DrugPipeline.netDrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-immunology-drugs-market-to-2022-new-report-launched-843163.htm

See the article here:
Global Immunology Drugs Market to 2022; New Report Launched - Digital Journal

Modius wants to zap your brain with neuroscience to fight the fat – Wareable

Can a wearable actually help you lose weight? British startup Neurovalens believes it's come up with one that will do just that.

It's launching its fat-fighting headset on Indiegogo today and it's looking to neuroscience to help the headgear do its magic.

Read this: Neuroscience wearables explained

So how does it work? Much like the Halo Sport and Thync neuroscience wearables we've covered before, the Modius headset is all about tapping into the part of the brain that is associated with and controls fat storage. It uses low-power electrical pulses to stimulate the vestibular nerve, which runs to the brain from behind the ear.

By stimulating the vestibular system for 45 minutes per day, the brain then interprets the stimulation as the body being more physically active, triggering the brain to reduce fat storage. This can in turn increase fat burning, decrease appetite and activate metabolic hormones. Apparently the evidence that vestibular stimulation can reduce body fat has been around for years, but this is the first time you'll be able to do it from a non-invasive wearable.

While that all sounds impressive, the question is whether it works. The startup, which was founded by neuroscientists Dr. Jason McKeown and Dr. Paul McGeoch, carried out research which showed that it does make a difference and found there was a reduction in body fat along with a change in metabolic hormones and a proportion of energy derived from fat metabolism.

"Within one hour, there was a significant change in both appetite and metabolic hormones insulin & leptin", said chief science officer McGeoch.

"There was also a significant increase in the proportion of energy derived from fat metabolism. And over a 16-week period, with an average of three hours use per week, the average reduction in central body fat was 8%, with a range of 2% to 16%. These studies were carried out without changes in either diet or exercise."

The Modius headset is available for pre-order now on Indiegogo and will be available to all in the autumn/fall. We'll be trying it out in the coming months to see if it can really deliver.

See the article here:
Modius wants to zap your brain with neuroscience to fight the fat - Wareable

Collaborative Co-Parenting and Heteronormativity: Recognising the Interests of Gay Fathers – Family Law

Philip Bremner,Lecturer, School of Law, University of Sussex

Keywords: same-sex parents - gay fathers - family law -assisted reproduction -procreative consciousness -multiple parents

Find out moreorrequest a free 1-week trialof Child and Family Law Quarterly. Please quote: 100482.

The article further argues that the lamentable lack of explicit judicial consideration of the interests of gay men involved in collaborative co-parenting reflects the gender-based disparity perpetuated by the parenthood provisions of the Human Fertilisation and Embryology Act 2008. These provide for the recognition without court involvement of women-led, homonuclear families but not male-led parenting. Therefore, courts must be sensitive to this disparity by explicitly considering the procreative consciousness of gay men, as they currently do with the potential vulnerability of women-led families. Only in this way, will judicial reasoning reflect the various interests at stake in collaborative co-parenting arrangements rather than privileging a particular family form.

Read the original here:
Collaborative Co-Parenting and Heteronormativity: Recognising the Interests of Gay Fathers - Family Law

You’re getting a DNA test — start-up Clear Genetics is building chatbots to help you understand the results – CNBC

George Frey | AFP | Getty Images

A lab technician at Myriad Genetics in Salt Lake City, Utah.

Thousands of people are getting genetic tests, for everything from their cancer risk to their likelihood of passing on a disease to a child.

But many doctors aren't adequately trained to interpret these results, or tell patients how to act on them. And genetic counselors -- who do have that knowledge -- are in short supply. There are only about 4,000 genetic counselors in the country today. That's one for every 80,000 Americans. That means some patients have to wait months to get a consultation.

Start-up Clear Genetics, which launches this week after raising $2.5 million in financing, is trying to make genetic expertise more widely available.

The start-up has developed a conversational chatbot to guide a user through their results, collect information and review options for genetic testing, and answer questions about things like whether the test will be covered by insurance. If there's a need for additional support, the patient can then schedule a consultation with a human expert via video or in-person.

"We're finding that it's working really well with patients," said Moran Snir, Clear Genetics' CEO, who was previously a software engineer with the Israeli military.

Clear Genetics is working with several large health systems in the United States to test out a beta version of its product.

"I think this is a very good use for AI," said David Ledbetter, executive vice president and chief scientific officer at hospital network Geisinger Health System, in an interview with CNBC.

Read the rest here:
You're getting a DNA test -- start-up Clear Genetics is building chatbots to help you understand the results - CNBC

UNH research: Genetics mechanism preventing kidney injury after severe dehydration – Foster’s Daily Democrat

DURHAM Millions of people die every year from dehydration as a result of exposure and illness. In humans, even the most minor dehydration can compromise the kidneys causing lifelong, irreparable issues or even death. However, some animals living in desert environments are able to survive both acute and chronic dehydration. While these animals, like cactus mice, have evolved over time to deal with environmental stressors like dehydration, researchers at the University of New Hampshire have found its not the physical makeup that is helping them survive, but rather their genetic makeup.

Initially, we thought that maybe their kidneys are structurally different from people, but theyre not, said Matt MacManes, assistant professor of genome enabled biology at UNH and lead author of the study. However, when exposed to acute dehydration, no kidney injury was apparent, which would definitely be the case for humans exposed to similar levels of dehydration, suggesting their genes may be whats preventing widespread kidney damage.

The kidney is the canary in the coal mine when it comes to dehydration, continues MacManes. The exciting outcome of this research is that the molecular toolkit of the cactus mouse has orthologues, or related genes, in humans. These provide the potential for development of drugs or other therapies that could help protect the human body from the damages of dehydration. Such a response could be extremely valuable in a wide variety of situations for people with renal failure, where water is severally limited due to geography or possibly global climate change, for troops deployed in the desert, and perhaps even in space travel.

To understand how desert-adapted cactus mice (Peromyscus eremicus) survive, the study recently published in the American Journal of Renal Physiology outlines how the researchers modeled a desert-like condition. The mice that went without water for 72 hours lost on average 23 percent of their body weight, which would be fatal for humans. Even though dehydrated, the mice continued to be active, eat, and interact normally. Researchers analyzed several other factors including serum electrolytes (sodium, calcium, bicarbonate ion) as well as blood urea nitrogen (BUN) and creatinine. While both were slightly elevated, gene-based biomarkers for kidney injury, were not, which suggests kidney injury is not occurring.

Further analysis found genes that are important in modulating electrolytes were very active, as were genes responsible for maintaining kidney blood pressure.

See original here:
UNH research: Genetics mechanism preventing kidney injury after severe dehydration - Foster's Daily Democrat

NSF Awards Grants To Kent Students – Patch.com

From Kent University: Several Kent State University professors in the College of Arts and Sciences have been selected to receive Research Experiences for Undergraduates (REU) grants from the National Science Foundation (NSF). REU grants are designed to provide faculty with funding to create research positions and experiences specifically for undergraduate students. These students typically come from two- or four-year institutions that may not provide access to many research opportunities.

Torsten Hegmann, Ph.D., a professor at Kent States Liquid Crystal Institute, and Mike Tubergen, Ph.D., a professor and chair in the Department of Chemistry and Biochemistry, were awarded $360,000 by the NSF in March for the support of an REU Site in liquid crystals and advanced materials at Kent State. The three-year award started June 1, 2017, and ends May 31, 2020.

The goal of this NSF-REU project is to provide a diverse group of undergraduate students with a comprehensive learning and career-building experience that has advanced materials chemistry at its core, yet seamlessly crosses the disciplinary boundaries among materials science, biology and chemical physics, Hegmann explained. Undergraduate students will conduct research in Kent States Department of Chemistry and Biochemistry, as well as the Liquid Crystal Institute, which are recognized centers of excellence in advanced materials, technology and education.

The NSF also offered an REU Site award of $259,200 to Evgenia Soprunova, Ph.D., and Mikhail Chebotar, Ph.D., both in the Department of Mathematical Sciences at Kent State, for undergraduate research in geometry, algebra and analysis. This award started May 1, 2017, and ends April 30, 2020.

Chebotar, whose students will be studying the interaction of linear algebra and ring theory, has had previous success with REU grants.

So far, I have supervised 15 REU students, and theyve published seven research papers, Chebotar said. Six of them were published in Linear Algebra and Its Applications, the top journal in the area of linear algebra, and one in Involve, a journal that showcases and encourages high-quality mathematical research involving students from all academic levels.

In addition to these faculty awards from the NSF, Taylor Michael, a biological sciences major at Kent State from Mantua, Ohio, is one of eight undergraduate students selected for the Ohio State Universitys Stone Laboratory 2017 REU Scholarship Program.

The five-week program is a competitive, comprehensive research internship that gives students the chance to conduct scientific research in the field alongside top scientists at Stone Laboratory, Ohio States island campus on Lake Erie.

REU students receive a full scholarship to Stone Lab, including lab fee, room and meals, in-state tuition for the 2-credit research experience and a 4-credit, five-week course. The program runs concurrently with Stone Labs five-week summer term. Students spend their nonclass days focused on research, working closely with their supervisors to design an experiment, collect samples and analyze data. At the end of the program, they give a final presentation to their peers and the public.

This years program was held June 18 through July 22. Michael studied field zoology.

More information about Stone Labs REU program can be found here.

For more information about Kent States College of Arts and Sciences, visit here.

Image via Pixabay

Get free real-time news alerts from the Kent Patch.

Thanks for your feedback! Now share it with your friends!

Thanks for your feedback.

Originally published August 7, 2017.

Continued here:
NSF Awards Grants To Kent Students - Patch.com

Literary critic Adam Kirsch is reading a page of Talmud a day, along with Jews around the world. – Tablet Magazine

Literary criticAdam Kirschis readinga page of Talmuda day, along with Jews around the world.

The Talmud is a compendium of laws and legal opinions, and it presupposes the existence of a functioning court system. But a Jewish court, a beit din, is different in fundamental ways from the court of a state like the United States or, for that matter, Israel. Instead of being appointed by the government and staffed by salaried professionals, a Jewish court is made up of expert rabbis resident in the area, who serve as volunteers. In most cases, three judges serve to constitute a court; in more serious cases, where capital or corporal punishment is on the agenda, 23 judges are required. This commingling of sacred and secular is fitting, because halakhah, Jewish law, is not simply a code for the regulation of human behavior. It is a set of commandments given by God (though elaborated by human interpreters). To be a judge is to fulfill a religious duty: God stands in the congregation of God; in the midst of the judges he judges, says Psalm 81.

Yet that duty, as Daf Yomi readers saw in chapter one of Tractate Sanhedrin, is an onerous one, for several reasons. It is unpaid labor, which makes it a financial burden: Ajudge does not do what is necessary to provide for the needs of his house, and he enters his house empty-handed, says Rav in Sanhedrin 7b. Worse, however, is the moral responsibility of judging: If only his entry will be as his departure, Rav continues, by which he means that a judge is lucky if he comes home at night as free from sin as when he left in the morning. Judges are only human, which means they will sometimes make mistakes, but these are mistakes with enormous spiritual and worldly consequences. A judge should always view himself as if a sword is placed between his thighs and Gehenna is opened up beneath him, says Rabbi Yonatan. One wrong move means going to hell.

No wonder that when Rav Huna was judging a case, he would gather and bring 10 rabbis from Ravs study hall, in order to share the burden of responsibility. As Yehoshua ben Levi says, If 10 judges are sitting in judgment, a prisoners collar hangs around all of their necks, since they will be punished by God for a false verdict: any judge who takes from this litigant and gives to that litigant unlawfully, the Holy One, Blessed be He, takes his soul from him. When he goes to the courtroom, a judge goes out to death. Indeed, the fate of the entire community rests on the actions of its judges: Every judge who does not judge according to absolute truth causes the Divine Presence to withdraw from Israel, the Gemara holds.

Yet the suspicion arises that perhaps the rabbis put such stress on the dangers of judging because the office also involved a certain temptationnot financial, but in terms of status. In Sanhedrin 7b, we read about how a convoy of scribes would follow Rav around, and crowds would carry Mar Zutra on their shoulders. The power of a judge added to the prestige of a Torah scholar is a heady mixture, and the best judges take care not to be intoxicated by it: For power is not forever, and does the crown endure for all generations? Mar Zutra would remind himself, using a verse from Proverbs.

It is because they recognized the moral responsibility of judging that the rabbis were so hesitant to impose extreme verdicts, especially the death penalty. The law code given in the Torah is full of capital crimes: everything from adultery to idol worship to violating Shabbat to disobeying your parents can be punished by death, often by the particularly horrible method of stoning. But by the Talmudic era, it is clear that judges had lost their taste for such bloody punishments. Indeed, they introduce such high barriers to the imposition of capital sentences that, in practice, the death penalty could almost never be used.

In Sanhedrin 9a, the Gemara lays down the procedural requirements for capital punishment: The court executes them only when the following elements are present: the congregation; and witnesses; and forewarning. The congregation of Israel imposes judgment by proxy, through the panel of judges. There must be two eyewitnesses to the crime, and those witnesses must have warned the suspect explicitly that he was about to commit a capital crime. Moreover, Rabbi Yehuda adds, the warning must include by which form of the death penalty he is to be killed. If the suspect is warned that he is liable to death, but not specifically liable to stoning or strangling, then he cannot be executed.

This rule raises the question of whether Jews can be expected to know Jewish law. Apparently, the rabbis believed that they could not. Even in the case of major crimes, a person would have to be explicitly informed about the potential consequences of his action, presumably because he didnt already know it. Only a minority of Jews could be assumed to be familiar with halakhah; these were the people known as chaverimliterally, friendswho were evidently a religious elite; comparable, perhaps, to the Orthodox today. So the question arises: Does a chaver need a forewarning before he commits a crime, or should it be assumed that he already knows the law? Here the rabbis disagree, with the majority sticking to the rule that forewarning is necessary. Evidently, the purpose of the warning is not only to inform the would-be criminal of the law but to give him an extra chance to desist.

Obviously, these requirements could almost never be met in real life, particularly in the case of sins like adultery, which generally take place without witnesses. But the rabbis go on to add even more barriers to a guilty verdict. According to Rabbi Meir, whose opinions usually form the basis of the Mishna, any inconsistency in the witnesses testimony, even the most trivial, is grounds for dismissing that testimony. Yochanan ben Zakkai once heard a case in which the testimony hinged, in an unexplained manner, on the stems of figsby which the Talmud seems to mean, the color and shape of the figs. When the two witnesses disagreed about this, Yochanan dismissed their testimony, causing the case to collapse.

The primary role played by witnesses in a Jewish court case raises an interesting question. Can the accused be a witness against himself? In Sanhedrin 9b, the Gemara considers of a man who is raped by another man. In this case, the victim can be considered a witness to the crime, so that only one additional witness is required to make the requisite two. These two can take it upon themselves to kill the rapist because they are carrying out Torah law.

To us, of course, the crime in this situation is the rape, not gay sex. But Leviticus holds that sodomy itself is a capital crime, even if the sex between men is consensual. This raises the question of what happens when the victim of sodomy engages in it voluntarily. Such a person, under Torah law, is considered wicked (rashah), and the Torah prohibits accepting the testimony of the wicked: Do not put your hand with a wicked person to be an unrighteous witness. So can a person convict himself of wickedness by confessing to it? There seems to be a logical contradiction involved: Acriminal who confesses is declaring himself a rashah, and the testimony of a rashah is inadmissible, so the testimony of the man that he is a rashah would be inadmissible as well.

According to Rava, this case falls under the category of testimony that is forbidden because it applies to a relative. Ordinarily, a man is not allowed to be a witness in a case involving a family member, whether he is testifying for or against the accused. Rava reasons that a person is his own relative, and so this rule extends to self-accusation: A person cannot render himself wicked by his own testimony. However, his testimony about the same incident would be considered reliable when it is directed against someone other than himself. This leads to the paradoxical result that, if two men have consensual sex, one can procure the execution of the other while remaining innocent himself. However, it can only be the passive partner in sodomy who makes the accusation, since in the eyes of the law he is the victim of the act, while the active partner is the guilty party. The absurdities of this situation are a good sign that it is criminalizing gay sex that is truly rashah.

***

Adam Kirsch embarked on theDaf Yomicycle of daily Talmud study inAugust2012. To catch up on the complete archive,click here.

Adam Kirsch is a poet and literary critic, whose books include The People and the Books: 18 Classics of Jewish Literature.

Go here to read the rest:
Literary critic Adam Kirsch is reading a page of Talmud a day, along with Jews around the world. - Tablet Magazine